Shopping Cart 0
Cart Subtotal
USD 0

Mylan NV (MYL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 750

Details

Summary

Mylan NV (Mylan) is a pharmaceutical company, which develops, licenses, manufactures, markets and distributes generics and branded medicines, and consumer healthcare products. It offers pharmaceutical products in multiple forms for various disease conditions related to respiratory and allergy, cardiovascular, dermatology, central nervous system (CNS) and cancer, besides anti-rretrovirals, anaphylaxis products and others. The company also offers active pharmaceutical ingredients (APIs). The company sells its products to retail pharmacy chains, wholesalers and distributors, group purchasing organizations, drug store chains, independent pharmacies, drug manufacturers, institutions, and public and governmental agencies. The company markets its products in various countries worldwide. Mylan is headquartered in Hatfield, Hertfordshire, the UK.

Mylan NV (MYL)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 6

List of Figures 7

Mylan NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 9

Mylan NV, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 10

Mylan NV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 11

Mylan NV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 12

Mylan NV, Medical Devices Deals, 2012 to YTD 2018 14

Mylan NV, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 15

Mylan NV, Pharmaceuticals & Healthcare, Deal Details 20

Asset Purchase 20

Mylan Acquires TOBI Podhaler and TOBI Solution from Novartis for USD463 Million 20

Mylan to Acquire Marketing Rights to GA Depot from Mapi Pharma 21

Mylan Acquires Global Rights to Cold-EEZE Brand from ProPhase Labs 22

Mylan Acquires Topical Pharmaceutical Business of Renaissance for up to USD1 Billion 23

Teva Pharma May Divest its Assets 24

Mylan Acquires Female Health Care Businesses from Famy Care for USD800 Million 26

Mylan Acquires Branded Generics Business of Abbott for USD5.3 Billion 28

Mylan to Acquire Rights to Arixtra Injection from Aspen Global 30

Mylan Acquires Rights To Lama Respiratory Compound From Pfizer 31

Mylan Completes Acquisition Of Drug Manufacturing Plant From Unichem For USD 30 Million 32

Rottapharm|Madaus Acquires Zyma Brands 33

Meda Acquires OTC Sleep Aid Product, MidNite 34

Mylan Labs To Acquire Manufacturing Unit Of SMS Pharma For USD 33 Million 35

Meda Completes Acquisition Of Women's Health Business From Jazz Pharma For USD 95 Million 36

Mylan Acquires Clindamycin Phosphate And Benzoyl Peroxide Gel From Valeant Pharma International 38

Private Equity 39

Ardian May Sell Riemser Pharma for USD494.3 Million 39

Riverside Acquires Euromed from Meda for USD86.7 Million 41

Sanofi Plans to Sell Portfolio of Mature Drugs for USD8.6 Billion 42

Partnerships 44

Mylan Enters Into Licensing Agreement With Biocon For Three Generic Insulin Products 44

Lupin and Mylan Enter into Partnership Agreement 45

Unimedic Enters into Distribution Agreement with Mylan 46

Mabion Enters into Distribution Agreement with Mylan 47

Pulmatrix Enters into Co-Development Agreement with Mylan 48

AB-Biotics Enters into Distribution Agreement with Mylan 49

Mylan Pharma Enters into Distribution Agreement with Gilead Sciences 50

Theravance Biopharma Enters into Development and Commercialization Agreement with Mylan 51

Meda Enters Promotion Agreement With Mission Pharmacal For Elestrin 52

Mylan Pharma Enters Into Distribution Agreement With Gilead Sciences 53

Venus Pharma Enters Into Co-Marketing Agreement With Mylan For Meropenem 54

Pfizer To Enter Into Co-Development Agreement With Mylan For Generic Drugs 55

Agila Specialties Forms Joint Venture With Jamp Pharma 56

Licensing Agreements 57

Mylan Enters into Licensing Agreement with AbbVie 57

Mylan Enters into Licensing Agreement with Fujifilm Kyowa Kirin Biologics 58

Mylan Enters into Licensing Agreement with Revance Therapeutics 59

Mylan Pharma Enters into Licensing Agreement with Otsuka Novel Products for Delamanid 60

Mylan Enters into Licensing Agreement with Genentech and Roche 61

Mylan Enters into Licensing Agreement with Medicines Patent Pool 62

Mylan Enters into Licensing Agreement with Medicines Patent Pool and Bristol-Myers Squibb Company for Daclatasvir 63

Mylan Enters into Licensing Agreement with Medicines Patent Pool and Bristol-Myers Squibb Company 64

Mylan Ireland Enters into Licensing Agreement with Momenta Pharma 65

Gilead Sciences Expands Licensing Agreement with Mylan Labs 67

Mylan Enters into Licensing Agreement with Medicines Patent Pool for HIV Medicines 68

Mylan Enters into Licensing Agreement with MPP and ViiV Healthcare for Dolutegravir 69

Phosphagenics Enters Into Licensing Agreement With Agila Specialties For TPM Technology 70

Gilead Sciences Expands Licensing Agreement with Mylan Labs 71

Gilead Sciences Enters into Licensing Agreement with Mylan Labs for Tenofovir Alafenamide 72

Venus Pharma Enters into Licensing Agreement with Mylan for Meropenem 73

Prosonix Enters Into Licensing Agreement With Mylan For PSX1001 And PSX1050 74

Mylan Enters Into Licensing Agreement With Orion for Stalevo 75

Mylan Specialty Enters Into Licensing Agreement With Pfizer For EpiPen 76

Mylan Labs Enters Into Licensing Agreement With Gilead Sciences For Generic Versions Of Emtricitabine 78

Equity Offering 79

Abbott Sells stock of Mylan for USD2.29 Billion 79

Meda to Raise USD278.7 Million in Rights Offering 80

Rottapharm Withdraws IPO for USD614.7 Million 82

Debt Offering 83

Mylan Raises USD589.4 Million in Private Offering of 2.125% Notes Due 2025 83

Mylan Raises USD589.3 Million in Public Offering of Notes 84

Mylan Prices Private Placement of 5.2% Notes Due 2048 for USD750 Million 85

Mylan Prices Private Placement of 4.55% Notes Due 2028 for USD750 Million 86

Mylan Raises USD551.6 Million in Public Offering of Bonds Due 2020 87

Mylan Raises USD796 Million in Private Placement of 1.25% Notes Due 2020 88

Mylan Raises USD796 Million in Private Placement of 3.125% Notes Due 2028 89

Mylan Raises USD1.06 Billion in Private Placement of 2.25% Notes Due 2024 90

Mylan Raises USD531 Million in Private Placement of Floating Rate Notes Due 2018 91

Mylan Raises USD2.25 Billion in Private Placement of 3.15% Notes Due 2021 92

Mylan Raises USD1 Billion in Private Placement of 2.5% Notes Due 2019 93

Mylan Raises USD2.25 Billion in Private Placement of 3.95% Notes Due 2026 94

Mylan Raises USD1 Billion in Private Placement of 5.25% Notes Due 2046 95

Mylan Raises USD500 Million in Private Placement 3.75% Notes Due 2020 96

Mylan Raises USD500 Million in Private Placement 3% Notes Due 2018 97

Mylan Completes Public Offering Of Notes Due 2043 For USD 500 Million 98

Mylan Completes Public Offering Of Notes Due 2016 For USD 500 Million 100

Mylan Completes Public Offering Of Notes Due 2023 For USD 500 Million 102

Mylan Completes Public Offering Of Notes Due 2019 For USD 500 Million 104

Mylan Completes Private Placement Of Notes Due 2018 For USD 650 Million 105

Mylan Completes Private Placement Of Notes Due 2016 For USD 500 Million 106

Meda Prices Public Offering Of Notes Due 2016 For USD 62 Million 107

Meda Prices Public Offering Of Notes Due 2018 For USD 92.4 Million 108

Mylan Completes Private Placement Of Notes Due 2023 For USD 750 Million 109

Asset Transactions 110

Recordati Acquires Rights to Cystagon from Mylan 110

Mylan Labs May Sell Manufacturing Facility 111

Acquisition 112

Mylan Acquires Meda for USD9.42 Billion 112

Mylan Acquires Meda for USD9.9 Billion 114

Teva Pharma, Mylan May Acquire Teut|Pfizer 116

Meda Acquires Rottapharm from Fidim for USD3 Billion 118

Fidim Acquires Rottapharm Biotech from Rottapharm 119

Meda Acquires ZpearPoint, Dental Products Provider 120

Mylan Completes Acquisition Of Agila Specialties From Strides Arcolab For Up To USD 1.75 Billion 121

Mylan Rumored To Acquire Bafna Pharma 124

Meda Completes Acquisition Of Acton Pharma For Up To USD 200 Million 125

Renaissance Acquisition Acquires DPT Labs, Contract Manufacturing Company 127

Mylan NV-Key Competitors 128

Mylan NV-Key Employees 129

Mylan NV-Locations And Subsidiaries 130

Head Office 130

Other Locations & Subsidiaries 130

Recent Developments 137

Financial Announcements 137

Sep 30, 2018: Mylan Reports Third Quarter 2018 Results and Reaffirms 2018 Guidance 137

Aug 08, 2018: Mylan reports second quarter 2018 results and updates 2018 guidance 142

May 09, 2018: Mylan Reports First Quarter 2018 Results and Reaffirms 2018 Guidance 146

Feb 28, 2018: Mylan Reports Full Year and Fourth Quarter 2017 Results and Provides 2018 Guidance 148

Nov 06, 2017: Mylan Reports Third Quarter 2017 Results and Updates 2017 Guidance 150

Aug 09, 2017: Mylan Reports Second Quarter 2017 Results and Updates 2017 Guidance 152

May 10, 2017: Mylan Reports First Quarter 2017 Results 156

Mar 01, 2017: Mylan Reports Fourth Quarter and Full Year 2016 Results and Provides 2017 Guidance 158

Corporate Communications 160

May 14, 2018: Mylan and West Virginia University Join Forces to Inspire West Virginia Youth Through STEM-CARE 160

Feb 26, 2018: 16-Year Veteran Director Wendy Cameron to Retire from Mylan Board after 2018 AGM 162

Nov 10, 2017: Mylan Announces Voluntary Delisting from the Tel Aviv Stock Exchange 163

Sep 13, 2017: Mylan Names Dennis Zeleny as Chief Human Relations Officer 164

May 01, 2017: Mylan Nominates Sjoerd Vollebregt for Election to Board of Directors 165

Mar 28, 2017: Mylan Names Former SEC Commissioner Daniel Gallagher as Chief Legal Officer 166

Legal and Regulatory 167

Jun 28, 2018: Mylan Statement: Morgantown Operations 167

Nov 06, 2017: Phosphagenics Mylan Arbitration Hearing Concluded 168

Oct 31, 2017: Mylan Provides Statement in Response to Announcement of Proposed Amendments to Civil Complaint 169

Appendix 170

Methodology 170

About GlobalData 170

Contact Us 170

Disclaimer 170


List Of Figure

List of Figures

Mylan NV, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Mylan NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Mylan NV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Mylan NV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Mylan NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 9

Mylan NV, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 10

Mylan NV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 11

Mylan NV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 12

Mylan NV, Medical Devices Deals, 2012 to YTD 2018 14


List Of Table

List of Tables

Mylan NV, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Mylan NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 9

Mylan NV, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 10

Mylan NV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 11

Mylan NV, Deals By Therapy Area, 2012 to YTD 2018 12

Mylan NV, Medical Devices Deals, 2012 to YTD 2018 14

Mylan NV, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 15

Mylan Acquires TOBI Podhaler and TOBI Solution from Novartis for USD463 Million 20

Mylan to Acquire Marketing Rights to GA Depot from Mapi Pharma 21

Mylan Acquires Global Rights to Cold-EEZE Brand from ProPhase Labs 22

Mylan Acquires Topical Pharmaceutical Business of Renaissance for up to USD1 Billion 23

Teva Pharma May Divest its Assets 24

Mylan Acquires Female Health Care Businesses from Famy Care for USD800 Million 26

Mylan Acquires Branded Generics Business of Abbott for USD5.3 Billion 28

Mylan to Acquire Rights to Arixtra Injection from Aspen Global 30

Mylan Acquires Rights To Lama Respiratory Compound From Pfizer 31

Mylan Completes Acquisition Of Drug Manufacturing Plant From Unichem For USD 30 Million 32

Rottapharm|Madaus Acquires Zyma Brands 33

Meda Acquires OTC Sleep Aid Product, MidNite 34

Mylan Labs To Acquire Manufacturing Unit Of SMS Pharma For USD 33 Million 35

Meda Completes Acquisition Of Women's Health Business From Jazz Pharma For USD 95 Million 36

Mylan Acquires Clindamycin Phosphate And Benzoyl Peroxide Gel From Valeant Pharma International 38

Ardian May Sell Riemser Pharma for USD494.3 Million 39

Riverside Acquires Euromed from Meda for USD86.7 Million 41

Sanofi Plans to Sell Portfolio of Mature Drugs for USD8.6 Billion 42

Mylan Enters Into Licensing Agreement With Biocon For Three Generic Insulin Products 44

Lupin and Mylan Enter into Partnership Agreement 45

Unimedic Enters into Distribution Agreement with Mylan 46

Mabion Enters into Distribution Agreement with Mylan 47

Pulmatrix Enters into Co-Development Agreement with Mylan 48

AB-Biotics Enters into Distribution Agreement with Mylan 49

Mylan Pharma Enters into Distribution Agreement with Gilead Sciences 50

Theravance Biopharma Enters into Development and Commercialization Agreement with Mylan 51

Meda Enters Promotion Agreement With Mission Pharmacal For Elestrin 52

Mylan Pharma Enters Into Distribution Agreement With Gilead Sciences 53

Venus Pharma Enters Into Co-Marketing Agreement With Mylan For Meropenem 54

Pfizer To Enter Into Co-Development Agreement With Mylan For Generic Drugs 55

Agila Specialties Forms Joint Venture With Jamp Pharma 56

Mylan Enters into Licensing Agreement with AbbVie 57

Mylan Enters into Licensing Agreement with Fujifilm Kyowa Kirin Biologics 58

Mylan Enters into Licensing Agreement with Revance Therapeutics 59

Mylan Pharma Enters into Licensing Agreement with Otsuka Novel Products for Delamanid 60

Mylan Enters into Licensing Agreement with Genentech and Roche 61

Mylan Enters into Licensing Agreement with Medicines Patent Pool 62

Mylan Enters into Licensing Agreement with Medicines Patent Pool and Bristol-Myers Squibb Company for Daclatasvir 63

Mylan Enters into Licensing Agreement with Medicines Patent Pool and Bristol-Myers Squibb Company 64

Mylan Ireland Enters into Licensing Agreement with Momenta Pharma 65

Gilead Sciences Expands Licensing Agreement with Mylan Labs 67

Mylan Enters into Licensing Agreement with Medicines Patent Pool for HIV Medicines 68

Mylan Enters into Licensing Agreement with MPP and ViiV Healthcare for Dolutegravir 69

Phosphagenics Enters Into Licensing Agreement With Agila Specialties For TPM Technology 70

Gilead Sciences Expands Licensing Agreement with Mylan Labs 71

Gilead Sciences Enters into Licensing Agreement with Mylan Labs for Tenofovir Alafenamide 72

Venus Pharma Enters into Licensing Agreement with Mylan for Meropenem 73

Prosonix Enters Into Licensing Agreement With Mylan For PSX1001 And PSX1050 74

Mylan Enters Into Licensing Agreement With Orion for Stalevo 75

Mylan Specialty Enters Into Licensing Agreement With Pfizer For EpiPen 76

Mylan Labs Enters Into Licensing Agreement With Gilead Sciences For Generic Versions Of Emtricitabine 78

Abbott Sells stock of Mylan for USD2.29 Billion 79

Meda to Raise USD278.7 Million in Rights Offering 80

Rottapharm Withdraws IPO for USD614.7 Million 82

Mylan Raises USD589.4 Million in Private Offering of 2.125% Notes Due 2025 83

Mylan Raises USD589.3 Million in Public Offering of Notes 84

Mylan Prices Private Placement of 5.2% Notes Due 2048 for USD750 Million 85

Mylan Prices Private Placement of 4.55% Notes Due 2028 for USD750 Million 86

Mylan Raises USD551.6 Million in Public Offering of Bonds Due 2020 87

Mylan Raises USD796 Million in Private Placement of 1.25% Notes Due 2020 88

Mylan Raises USD796 Million in Private Placement of 3.125% Notes Due 2028 89

Mylan Raises USD1.06 Billion in Private Placement of 2.25% Notes Due 2024 90

Mylan Raises USD531 Million in Private Placement of Floating Rate Notes Due 2018 91

Mylan Raises USD2.25 Billion in Private Placement of 3.15% Notes Due 2021 92

Mylan Raises USD1 Billion in Private Placement of 2.5% Notes Due 2019 93

Mylan Raises USD2.25 Billion in Private Placement of 3.95% Notes Due 2026 94

Mylan Raises USD1 Billion in Private Placement of 5.25% Notes Due 2046 95

Mylan Raises USD500 Million in Private Placement 3.75% Notes Due 2020 96

Mylan Raises USD500 Million in Private Placement 3% Notes Due 2018 97

Mylan Completes Public Offering Of Notes Due 2043 For USD 500 Million 98

Mylan Completes Public Offering Of Notes Due 2016 For USD 500 Million 100

Mylan Completes Public Offering Of Notes Due 2023 For USD 500 Million 102

Mylan Completes Public Offering Of Notes Due 2019 For USD 500 Million 104

Mylan Completes Private Placement Of Notes Due 2018 For USD 650 Million 105

Mylan Completes Private Placement Of Notes Due 2016 For USD 500 Million 106

Meda Prices Public Offering Of Notes Due 2016 For USD 62 Million 107

Meda Prices Public Offering Of Notes Due 2018 For USD 92.4 Million 108

Mylan Completes Private Placement Of Notes Due 2023 For USD 750 Million 109

Recordati Acquires Rights to Cystagon from Mylan 110

Mylan Labs May Sell Manufacturing Facility 111

Mylan Acquires Meda for USD9.42 Billion 112

Mylan Acquires Meda for USD9.9 Billion 114

Teva Pharma, Mylan May Acquire Teut|Pfizer 116

Meda Acquires Rottapharm from Fidim for USD3 Billion 118

Fidim Acquires Rottapharm Biotech from Rottapharm 119

Meda Acquires ZpearPoint, Dental Products Provider 120

Mylan Completes Acquisition Of Agila Specialties From Strides Arcolab For Up To USD 1.75 Billion 121

Mylan Rumored To Acquire Bafna Pharma 124

Meda Completes Acquisition Of Acton Pharma For Up To USD 200 Million 125

Renaissance Acquisition Acquires DPT Labs, Contract Manufacturing Company 127

Mylan NV, Key Competitors 128

Mylan NV, Key Employees 129

Mylan NV, Other Locations 130

Mylan NV, Subsidiaries 131

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Mylan NV, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

Mylan NV (Mylan) is a pharmaceutical company, which develops, licenses, manufactures, markets and distributes generics and branded medicines, and consumer healthcare products. It offers pharmaceutical products in multiple forms for various disease conditions related to respiratory and allergy, cardiovascular, dermatology, central nervous system (CNS) and cancer, besides anti-rretrovirals, anaphylaxis products and others. The company also offers active pharmaceutical ingredients (APIs). The company sells its products to retail pharmacy chains, wholesalers and distributors, group purchasing organizations, drug store chains, independent pharmacies, drug manufacturers, institutions, and public and governmental agencies. The company markets its products in various countries worldwide. Mylan is headquartered in Hatfield, Hertfordshire, the UK.

Mylan NV (MYL)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 6

List of Figures 7

Mylan NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 9

Mylan NV, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 10

Mylan NV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 11

Mylan NV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 12

Mylan NV, Medical Devices Deals, 2012 to YTD 2018 14

Mylan NV, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 15

Mylan NV, Pharmaceuticals & Healthcare, Deal Details 20

Asset Purchase 20

Mylan Acquires TOBI Podhaler and TOBI Solution from Novartis for USD463 Million 20

Mylan to Acquire Marketing Rights to GA Depot from Mapi Pharma 21

Mylan Acquires Global Rights to Cold-EEZE Brand from ProPhase Labs 22

Mylan Acquires Topical Pharmaceutical Business of Renaissance for up to USD1 Billion 23

Teva Pharma May Divest its Assets 24

Mylan Acquires Female Health Care Businesses from Famy Care for USD800 Million 26

Mylan Acquires Branded Generics Business of Abbott for USD5.3 Billion 28

Mylan to Acquire Rights to Arixtra Injection from Aspen Global 30

Mylan Acquires Rights To Lama Respiratory Compound From Pfizer 31

Mylan Completes Acquisition Of Drug Manufacturing Plant From Unichem For USD 30 Million 32

Rottapharm|Madaus Acquires Zyma Brands 33

Meda Acquires OTC Sleep Aid Product, MidNite 34

Mylan Labs To Acquire Manufacturing Unit Of SMS Pharma For USD 33 Million 35

Meda Completes Acquisition Of Women's Health Business From Jazz Pharma For USD 95 Million 36

Mylan Acquires Clindamycin Phosphate And Benzoyl Peroxide Gel From Valeant Pharma International 38

Private Equity 39

Ardian May Sell Riemser Pharma for USD494.3 Million 39

Riverside Acquires Euromed from Meda for USD86.7 Million 41

Sanofi Plans to Sell Portfolio of Mature Drugs for USD8.6 Billion 42

Partnerships 44

Mylan Enters Into Licensing Agreement With Biocon For Three Generic Insulin Products 44

Lupin and Mylan Enter into Partnership Agreement 45

Unimedic Enters into Distribution Agreement with Mylan 46

Mabion Enters into Distribution Agreement with Mylan 47

Pulmatrix Enters into Co-Development Agreement with Mylan 48

AB-Biotics Enters into Distribution Agreement with Mylan 49

Mylan Pharma Enters into Distribution Agreement with Gilead Sciences 50

Theravance Biopharma Enters into Development and Commercialization Agreement with Mylan 51

Meda Enters Promotion Agreement With Mission Pharmacal For Elestrin 52

Mylan Pharma Enters Into Distribution Agreement With Gilead Sciences 53

Venus Pharma Enters Into Co-Marketing Agreement With Mylan For Meropenem 54

Pfizer To Enter Into Co-Development Agreement With Mylan For Generic Drugs 55

Agila Specialties Forms Joint Venture With Jamp Pharma 56

Licensing Agreements 57

Mylan Enters into Licensing Agreement with AbbVie 57

Mylan Enters into Licensing Agreement with Fujifilm Kyowa Kirin Biologics 58

Mylan Enters into Licensing Agreement with Revance Therapeutics 59

Mylan Pharma Enters into Licensing Agreement with Otsuka Novel Products for Delamanid 60

Mylan Enters into Licensing Agreement with Genentech and Roche 61

Mylan Enters into Licensing Agreement with Medicines Patent Pool 62

Mylan Enters into Licensing Agreement with Medicines Patent Pool and Bristol-Myers Squibb Company for Daclatasvir 63

Mylan Enters into Licensing Agreement with Medicines Patent Pool and Bristol-Myers Squibb Company 64

Mylan Ireland Enters into Licensing Agreement with Momenta Pharma 65

Gilead Sciences Expands Licensing Agreement with Mylan Labs 67

Mylan Enters into Licensing Agreement with Medicines Patent Pool for HIV Medicines 68

Mylan Enters into Licensing Agreement with MPP and ViiV Healthcare for Dolutegravir 69

Phosphagenics Enters Into Licensing Agreement With Agila Specialties For TPM Technology 70

Gilead Sciences Expands Licensing Agreement with Mylan Labs 71

Gilead Sciences Enters into Licensing Agreement with Mylan Labs for Tenofovir Alafenamide 72

Venus Pharma Enters into Licensing Agreement with Mylan for Meropenem 73

Prosonix Enters Into Licensing Agreement With Mylan For PSX1001 And PSX1050 74

Mylan Enters Into Licensing Agreement With Orion for Stalevo 75

Mylan Specialty Enters Into Licensing Agreement With Pfizer For EpiPen 76

Mylan Labs Enters Into Licensing Agreement With Gilead Sciences For Generic Versions Of Emtricitabine 78

Equity Offering 79

Abbott Sells stock of Mylan for USD2.29 Billion 79

Meda to Raise USD278.7 Million in Rights Offering 80

Rottapharm Withdraws IPO for USD614.7 Million 82

Debt Offering 83

Mylan Raises USD589.4 Million in Private Offering of 2.125% Notes Due 2025 83

Mylan Raises USD589.3 Million in Public Offering of Notes 84

Mylan Prices Private Placement of 5.2% Notes Due 2048 for USD750 Million 85

Mylan Prices Private Placement of 4.55% Notes Due 2028 for USD750 Million 86

Mylan Raises USD551.6 Million in Public Offering of Bonds Due 2020 87

Mylan Raises USD796 Million in Private Placement of 1.25% Notes Due 2020 88

Mylan Raises USD796 Million in Private Placement of 3.125% Notes Due 2028 89

Mylan Raises USD1.06 Billion in Private Placement of 2.25% Notes Due 2024 90

Mylan Raises USD531 Million in Private Placement of Floating Rate Notes Due 2018 91

Mylan Raises USD2.25 Billion in Private Placement of 3.15% Notes Due 2021 92

Mylan Raises USD1 Billion in Private Placement of 2.5% Notes Due 2019 93

Mylan Raises USD2.25 Billion in Private Placement of 3.95% Notes Due 2026 94

Mylan Raises USD1 Billion in Private Placement of 5.25% Notes Due 2046 95

Mylan Raises USD500 Million in Private Placement 3.75% Notes Due 2020 96

Mylan Raises USD500 Million in Private Placement 3% Notes Due 2018 97

Mylan Completes Public Offering Of Notes Due 2043 For USD 500 Million 98

Mylan Completes Public Offering Of Notes Due 2016 For USD 500 Million 100

Mylan Completes Public Offering Of Notes Due 2023 For USD 500 Million 102

Mylan Completes Public Offering Of Notes Due 2019 For USD 500 Million 104

Mylan Completes Private Placement Of Notes Due 2018 For USD 650 Million 105

Mylan Completes Private Placement Of Notes Due 2016 For USD 500 Million 106

Meda Prices Public Offering Of Notes Due 2016 For USD 62 Million 107

Meda Prices Public Offering Of Notes Due 2018 For USD 92.4 Million 108

Mylan Completes Private Placement Of Notes Due 2023 For USD 750 Million 109

Asset Transactions 110

Recordati Acquires Rights to Cystagon from Mylan 110

Mylan Labs May Sell Manufacturing Facility 111

Acquisition 112

Mylan Acquires Meda for USD9.42 Billion 112

Mylan Acquires Meda for USD9.9 Billion 114

Teva Pharma, Mylan May Acquire Teut|Pfizer 116

Meda Acquires Rottapharm from Fidim for USD3 Billion 118

Fidim Acquires Rottapharm Biotech from Rottapharm 119

Meda Acquires ZpearPoint, Dental Products Provider 120

Mylan Completes Acquisition Of Agila Specialties From Strides Arcolab For Up To USD 1.75 Billion 121

Mylan Rumored To Acquire Bafna Pharma 124

Meda Completes Acquisition Of Acton Pharma For Up To USD 200 Million 125

Renaissance Acquisition Acquires DPT Labs, Contract Manufacturing Company 127

Mylan NV-Key Competitors 128

Mylan NV-Key Employees 129

Mylan NV-Locations And Subsidiaries 130

Head Office 130

Other Locations & Subsidiaries 130

Recent Developments 137

Financial Announcements 137

Sep 30, 2018: Mylan Reports Third Quarter 2018 Results and Reaffirms 2018 Guidance 137

Aug 08, 2018: Mylan reports second quarter 2018 results and updates 2018 guidance 142

May 09, 2018: Mylan Reports First Quarter 2018 Results and Reaffirms 2018 Guidance 146

Feb 28, 2018: Mylan Reports Full Year and Fourth Quarter 2017 Results and Provides 2018 Guidance 148

Nov 06, 2017: Mylan Reports Third Quarter 2017 Results and Updates 2017 Guidance 150

Aug 09, 2017: Mylan Reports Second Quarter 2017 Results and Updates 2017 Guidance 152

May 10, 2017: Mylan Reports First Quarter 2017 Results 156

Mar 01, 2017: Mylan Reports Fourth Quarter and Full Year 2016 Results and Provides 2017 Guidance 158

Corporate Communications 160

May 14, 2018: Mylan and West Virginia University Join Forces to Inspire West Virginia Youth Through STEM-CARE 160

Feb 26, 2018: 16-Year Veteran Director Wendy Cameron to Retire from Mylan Board after 2018 AGM 162

Nov 10, 2017: Mylan Announces Voluntary Delisting from the Tel Aviv Stock Exchange 163

Sep 13, 2017: Mylan Names Dennis Zeleny as Chief Human Relations Officer 164

May 01, 2017: Mylan Nominates Sjoerd Vollebregt for Election to Board of Directors 165

Mar 28, 2017: Mylan Names Former SEC Commissioner Daniel Gallagher as Chief Legal Officer 166

Legal and Regulatory 167

Jun 28, 2018: Mylan Statement: Morgantown Operations 167

Nov 06, 2017: Phosphagenics Mylan Arbitration Hearing Concluded 168

Oct 31, 2017: Mylan Provides Statement in Response to Announcement of Proposed Amendments to Civil Complaint 169

Appendix 170

Methodology 170

About GlobalData 170

Contact Us 170

Disclaimer 170


List Of Figure

List of Figures

Mylan NV, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Mylan NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Mylan NV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Mylan NV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Mylan NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 9

Mylan NV, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 10

Mylan NV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 11

Mylan NV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 12

Mylan NV, Medical Devices Deals, 2012 to YTD 2018 14


List Of Table

List of Tables

Mylan NV, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Mylan NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 9

Mylan NV, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 10

Mylan NV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 11

Mylan NV, Deals By Therapy Area, 2012 to YTD 2018 12

Mylan NV, Medical Devices Deals, 2012 to YTD 2018 14

Mylan NV, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 15

Mylan Acquires TOBI Podhaler and TOBI Solution from Novartis for USD463 Million 20

Mylan to Acquire Marketing Rights to GA Depot from Mapi Pharma 21

Mylan Acquires Global Rights to Cold-EEZE Brand from ProPhase Labs 22

Mylan Acquires Topical Pharmaceutical Business of Renaissance for up to USD1 Billion 23

Teva Pharma May Divest its Assets 24

Mylan Acquires Female Health Care Businesses from Famy Care for USD800 Million 26

Mylan Acquires Branded Generics Business of Abbott for USD5.3 Billion 28

Mylan to Acquire Rights to Arixtra Injection from Aspen Global 30

Mylan Acquires Rights To Lama Respiratory Compound From Pfizer 31

Mylan Completes Acquisition Of Drug Manufacturing Plant From Unichem For USD 30 Million 32

Rottapharm|Madaus Acquires Zyma Brands 33

Meda Acquires OTC Sleep Aid Product, MidNite 34

Mylan Labs To Acquire Manufacturing Unit Of SMS Pharma For USD 33 Million 35

Meda Completes Acquisition Of Women's Health Business From Jazz Pharma For USD 95 Million 36

Mylan Acquires Clindamycin Phosphate And Benzoyl Peroxide Gel From Valeant Pharma International 38

Ardian May Sell Riemser Pharma for USD494.3 Million 39

Riverside Acquires Euromed from Meda for USD86.7 Million 41

Sanofi Plans to Sell Portfolio of Mature Drugs for USD8.6 Billion 42

Mylan Enters Into Licensing Agreement With Biocon For Three Generic Insulin Products 44

Lupin and Mylan Enter into Partnership Agreement 45

Unimedic Enters into Distribution Agreement with Mylan 46

Mabion Enters into Distribution Agreement with Mylan 47

Pulmatrix Enters into Co-Development Agreement with Mylan 48

AB-Biotics Enters into Distribution Agreement with Mylan 49

Mylan Pharma Enters into Distribution Agreement with Gilead Sciences 50

Theravance Biopharma Enters into Development and Commercialization Agreement with Mylan 51

Meda Enters Promotion Agreement With Mission Pharmacal For Elestrin 52

Mylan Pharma Enters Into Distribution Agreement With Gilead Sciences 53

Venus Pharma Enters Into Co-Marketing Agreement With Mylan For Meropenem 54

Pfizer To Enter Into Co-Development Agreement With Mylan For Generic Drugs 55

Agila Specialties Forms Joint Venture With Jamp Pharma 56

Mylan Enters into Licensing Agreement with AbbVie 57

Mylan Enters into Licensing Agreement with Fujifilm Kyowa Kirin Biologics 58

Mylan Enters into Licensing Agreement with Revance Therapeutics 59

Mylan Pharma Enters into Licensing Agreement with Otsuka Novel Products for Delamanid 60

Mylan Enters into Licensing Agreement with Genentech and Roche 61

Mylan Enters into Licensing Agreement with Medicines Patent Pool 62

Mylan Enters into Licensing Agreement with Medicines Patent Pool and Bristol-Myers Squibb Company for Daclatasvir 63

Mylan Enters into Licensing Agreement with Medicines Patent Pool and Bristol-Myers Squibb Company 64

Mylan Ireland Enters into Licensing Agreement with Momenta Pharma 65

Gilead Sciences Expands Licensing Agreement with Mylan Labs 67

Mylan Enters into Licensing Agreement with Medicines Patent Pool for HIV Medicines 68

Mylan Enters into Licensing Agreement with MPP and ViiV Healthcare for Dolutegravir 69

Phosphagenics Enters Into Licensing Agreement With Agila Specialties For TPM Technology 70

Gilead Sciences Expands Licensing Agreement with Mylan Labs 71

Gilead Sciences Enters into Licensing Agreement with Mylan Labs for Tenofovir Alafenamide 72

Venus Pharma Enters into Licensing Agreement with Mylan for Meropenem 73

Prosonix Enters Into Licensing Agreement With Mylan For PSX1001 And PSX1050 74

Mylan Enters Into Licensing Agreement With Orion for Stalevo 75

Mylan Specialty Enters Into Licensing Agreement With Pfizer For EpiPen 76

Mylan Labs Enters Into Licensing Agreement With Gilead Sciences For Generic Versions Of Emtricitabine 78

Abbott Sells stock of Mylan for USD2.29 Billion 79

Meda to Raise USD278.7 Million in Rights Offering 80

Rottapharm Withdraws IPO for USD614.7 Million 82

Mylan Raises USD589.4 Million in Private Offering of 2.125% Notes Due 2025 83

Mylan Raises USD589.3 Million in Public Offering of Notes 84

Mylan Prices Private Placement of 5.2% Notes Due 2048 for USD750 Million 85

Mylan Prices Private Placement of 4.55% Notes Due 2028 for USD750 Million 86

Mylan Raises USD551.6 Million in Public Offering of Bonds Due 2020 87

Mylan Raises USD796 Million in Private Placement of 1.25% Notes Due 2020 88

Mylan Raises USD796 Million in Private Placement of 3.125% Notes Due 2028 89

Mylan Raises USD1.06 Billion in Private Placement of 2.25% Notes Due 2024 90

Mylan Raises USD531 Million in Private Placement of Floating Rate Notes Due 2018 91

Mylan Raises USD2.25 Billion in Private Placement of 3.15% Notes Due 2021 92

Mylan Raises USD1 Billion in Private Placement of 2.5% Notes Due 2019 93

Mylan Raises USD2.25 Billion in Private Placement of 3.95% Notes Due 2026 94

Mylan Raises USD1 Billion in Private Placement of 5.25% Notes Due 2046 95

Mylan Raises USD500 Million in Private Placement 3.75% Notes Due 2020 96

Mylan Raises USD500 Million in Private Placement 3% Notes Due 2018 97

Mylan Completes Public Offering Of Notes Due 2043 For USD 500 Million 98

Mylan Completes Public Offering Of Notes Due 2016 For USD 500 Million 100

Mylan Completes Public Offering Of Notes Due 2023 For USD 500 Million 102

Mylan Completes Public Offering Of Notes Due 2019 For USD 500 Million 104

Mylan Completes Private Placement Of Notes Due 2018 For USD 650 Million 105

Mylan Completes Private Placement Of Notes Due 2016 For USD 500 Million 106

Meda Prices Public Offering Of Notes Due 2016 For USD 62 Million 107

Meda Prices Public Offering Of Notes Due 2018 For USD 92.4 Million 108

Mylan Completes Private Placement Of Notes Due 2023 For USD 750 Million 109

Recordati Acquires Rights to Cystagon from Mylan 110

Mylan Labs May Sell Manufacturing Facility 111

Mylan Acquires Meda for USD9.42 Billion 112

Mylan Acquires Meda for USD9.9 Billion 114

Teva Pharma, Mylan May Acquire Teut|Pfizer 116

Meda Acquires Rottapharm from Fidim for USD3 Billion 118

Fidim Acquires Rottapharm Biotech from Rottapharm 119

Meda Acquires ZpearPoint, Dental Products Provider 120

Mylan Completes Acquisition Of Agila Specialties From Strides Arcolab For Up To USD 1.75 Billion 121

Mylan Rumored To Acquire Bafna Pharma 124

Meda Completes Acquisition Of Acton Pharma For Up To USD 200 Million 125

Renaissance Acquisition Acquires DPT Labs, Contract Manufacturing Company 127

Mylan NV, Key Competitors 128

Mylan NV, Key Employees 129

Mylan NV, Other Locations 130

Mylan NV, Subsidiaries 131

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Mylan NV, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.